Steve Hoerter

After 17 years of clinical work, Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) finally has a marketable product. The Food and Drug Administration approved Qinlock as a fourth-line treatment of gastrointestinal stromal tumors earlier this month.  The kinase inhibitor will be Deciphera...